Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax, Lenalidomide and Rituximab in Relapsed/Refractory Mantle Cell Lymphoma
NCT03505944Phase 2Unknown
- Sponsor
- Nordic Lymphoma Group
- Start
- Jul 2018
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of venetoclax in mantle cell lymphoma (MCL), sponsored by Nordic Lymphoma Group. Status: unknown.
02
Drugs
venetoclax
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03505944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03505944.